SCIENTISTS at Cambridge University's Department of Pathology have found an effective way of treating patients with long-standing rheumatoid arthritis, using "humanised monoclonal antibodies". Produced from animal cells, monoclonal antibodies are designed to order and can kill unwanted cells. Mainly used to treat cancer, these antibodies are now being used to kill rheumatoid arthritis-causing blood cells as well.
Monoclonal antibodies produced from animal cells have to be "humanised" using genetic engineering techniques that disguise them as a normal antibody, to prevent rejection by the patient's body.
CAMPATH-1H, the humanised monoclonal antibody used in rheumatoid arthritis treatment, is being produced by the MRC/Wellcome Therapeutic Antibody Centre at Addenbrookes' Hospital in Cambridge. Studies have shown that though repeated treatment prolongs the patient's symptomatic relief, it does not provide a permanent cure.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.